💊
Lorviqua
lorlatinib
Carcinoma, Pulmão Não Pequenas Células
✅ Autorizado
✅
Nenhum alerta ativo
Este medicamento não apresenta escassez contínua, cartas de segurança ou recolhimentos.
Para que serve
Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK?positive advanced NSCLC whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.
⚠️ Segurança do paciente
No
Página oficial da EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua